IP Library Granted Patent US 12,157,723
Granted Patent B2
US 12,157,723 · App. 18/152,465 · Granted Dec 3, 2024

Compounds

Inventors: Peter Rands (London, GB); George Knight (London, GB); Richard Chubb (London, GB); Derek Londesbrough (London, GB); Tiffanie Benway (London, GB); Zelah Joel (London, GB)
Assignee: CYBIN UK LTD
C07D209/16C07D209/20C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,157,723
App. No.
18/152,465
Granted
Dec 3, 2024
Kind
B2
Abstract

The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the α-position and consequently have improved oral bioavailability relative to α-diprotic analogues.

Claims (30)

1. A method of treating a psychiatric or neurological disorder in a patient in need thereof, comprising administering to the patient in need thereof a compound of formula I, or a pharmaceutically acceptable salt thereof:

wherein x H is protium or deuterium,

n is selected from 1, 2, 3 or 4,

R 1 is independently selected from —R 3 , —OR 3 , —O(CO)R 3 , —F, —Cl, —Br or —I, and

R 2 and R 3 are independently selected from C 1 -C 4 alkyl.

2. The method of claim 1 , wherein the psychiatric or neurological disorder is selected from (i) an obsessive compulsive disorder, (ii) a depressive disorder, (iii) a schizophrenia disorder, (iv) a schizotypal disorder, (v) an anxiety disorder, (vi) substance abuse, and (vii) an avolition disorder.

3. The method of claim 1 , wherein the disorder is major depressive disorder.

4. The method of claim 1 , wherein the disorder is treatment resistant depression.

5. The method of claim 1 , wherein said administering is accomplished by oral administration.

6. The method of claim 1 , wherein R 2 is methyl, or wherein R 1 is independently selected from OR 3 and —O(CO)R 3 , or wherein R 3 is methyl, or wherein R 1 is methoxy, or wherein n is 1, or wherein R 1 is at the 4- or 5-position, or wherein x H is deuterium.

7. The method of claim 1 , wherein n is 1 and R 1 is 5-methoxy.

8. The method of claim 1 , wherein the compound of formula I has a purity of between 99% and 100% by HPLC.

9. The method of claim 1 , wherein the compound of formula I is in the form of a pharmaceutically acceptable salt.

10. The method of claim 9 , wherein the pharmaceutically acceptable salt is a fumarate salt.

11. A method of treating a psychiatric or neurological disorder in a patient in need thereof, comprising administering to the patient in need thereof a pharmaceutical composition comprising:

a) a compound of formula I in the form of a pharmaceutically acceptable salt,

wherein x H is protium or deuterium,

n is selected from 1, 2, 3 or 4,

R 1 is independently selected from —R 3 , —OR 3 , —O(CO)R 3 , —F, —Cl, —Br or —I, and

R 2 and R 3 are independently selected from C 1 -C 4 alkyl; and

b) a pharmaceutically acceptably excipient.

12. The method of claim 11 , wherein the psychiatric or neurological disorder is selected from (i) an obsessive compulsive disorder, (ii) a depressive disorder, (iii) a schizophrenia disorder, (iv) a schizotypal disorder, (v) an anxiety disorder, (vi) substance abuse, and (vii) an avolition disorder.

13. The method of claim 11 , wherein the disorder is major depressive disorder.

14. The method of claim 11 , wherein the disorder is treatment resistant depression.

15. The method of claim 11 , wherein said administering is accomplished by oral administration.

16. A method of treating a psychiatric or neurological disorder in a patient in need thereof, comprising administering to the patient in need thereof a composition comprising at least a first and a second compound, or pharmaceutically acceptable salts thereof, wherein the first compound is selected from a compound of formula I as defined in claim 1 , and the second compound is an undeuterated analogue of the first compound.

17. The method of claim 16 , wherein the psychiatric or neurological disorder is selected from (i) an obsessive compulsive disorder, (ii) a depressive disorder, (iii) a schizophrenia disorder, (iv) a schizotypal disorder, (v) an anxiety disorder, (vi) substance abuse, and (vii) an avolition disorder.

18. The method of claim 16 , wherein the disorder is major depressive disorder.

19. The method of claim 16 , wherein the disorder is treatment resistant depression.

20. The method of claim 16 , wherein said administering is accomplished by oral administration.

Assignments (2)
CHANGE OF NAME Recorded Jan 16, 2024
From: SMALL PHARMA LTD.
To: CYBIN UK LTD
Reel/Frame 066131/0335 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2023
From: RANDS, PETER; BENWAY, TIFFANIE; JOEL, ZELAH; CHUBB, RICHARD; LONDESBROUGH, DEREK; KNIGHT, GEORGE
To: SMALL PHARMA LTD.
Reel/Frame 062329/0917 →
Priority Claims (3)
GB 1916210 · Nov 7, 2019 · national
GB 1917320 · Nov 28, 2019 · national
GB 2008303 · Jun 2, 2020 · national
Continuity (3)
Division 17662261 · May 6, 2022
Continuation PCTEP2020081502 · Nov 9, 2020
Related Publication 20230167056A1 · Jun 1, 2023
Cited By (1)
US 12,649,718